BioWorld Asia

Jan. 5, 2005

View Archived Issues

Neuro3d's Third Round: EUR31.5M For Development Of Lead Drugs

PARIS - Neuro3d closed a third round of financing in which it raised €31.5 million (US$41.6 million) from eight European venture capital funds. (BioWorld International) Read More

Arrow Spins Out Immunoprime To Focus On Infectious Disease

Read More

New Study Highlights Cell Cycle Regulation Intricacy

Read More

BioAlliance Pharma To File In EU For Miconazole Lauriad Approval

Read More

Stem Cell Foundation Planned To Help Bridge UK Funding Gap

Read More

Other News To Note

Read More